Last reviewed · How we verify
Dual antiplatelet therapy
Dual antiplatelet therapy is a Small molecule drug developed by McMaster University. It is currently FDA-approved. Also known as: Aspirin, Plavix, Brilinta, Effient.
At a glance
| Generic name | Dual antiplatelet therapy |
|---|---|
| Also known as | Aspirin, Plavix, Brilinta, Effient, Dual Antiplatelet Therapy |
| Sponsor | McMaster University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (PHASE3)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Comparing Two PFO Closure Devices in Adults With Previous Stroke or TIA (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Randomized Active-Controlled Trial Evaluating Fexuprazan (Fexuclue Tab) for Prevention Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy After Coronary Intervention (NA)
- The 10-Year Extended Follow-up of the DACAB Trial
- Chaigui Longmu Ejiao Paste for Ischemic Heart Disease (PHASE2)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dual antiplatelet therapy CI brief — competitive landscape report
- Dual antiplatelet therapy updates RSS · CI watch RSS
- McMaster University portfolio CI
Frequently asked questions about Dual antiplatelet therapy
What is Dual antiplatelet therapy?
Dual antiplatelet therapy is a Small molecule drug developed by McMaster University.
Who makes Dual antiplatelet therapy?
Dual antiplatelet therapy is developed and marketed by McMaster University (see full McMaster University pipeline at /company/mcmaster-university).
Is Dual antiplatelet therapy also known as anything else?
Dual antiplatelet therapy is also known as Aspirin, Plavix, Brilinta, Effient, Dual Antiplatelet Therapy.
What development phase is Dual antiplatelet therapy in?
Dual antiplatelet therapy is FDA-approved (marketed).
Related
- Manufacturer: McMaster University — full pipeline
- Also known as: Aspirin, Plavix, Brilinta, Effient, Dual Antiplatelet Therapy
- Compare: Dual antiplatelet therapy vs similar drugs
- Pricing: Dual antiplatelet therapy cost, discount & access